Discrete PEG Synthesis via Segmentation for Monodispersity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The use of polyethylene glycols (PEGs) in modifying therapeutic agents is hindered by the polydispersity of commercially available PEGs, leading to heterogeneity, limited molecular weight options, and reproducibility issues in drug delivery systems, particularly due to their polydisperse and multicomponent nature.
Innovation Solution
A novel method for synthesizing discrete polyethylene glycol (dPEG) compounds with a predetermined number of ethylene oxide units using a convergent or stepwise approach, allowing for the production of homo- and heterofunctional, branched species with improved purity and control over molecular weight, enabling more efficient and versatile applications in diagnostics and therapeutics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If commercially available polyethylene glycols are used, then a wide range of applications in plasticizers, cosmetics, pharmaceuticals, and biotechnical fields is enabled, but polydispersity leads to heterogeneity and limited molecular weight options
Solution Approach 1:
The invention segments the polyethylene glycol synthesis into discrete oligomer units with specific numbers of ethylene oxide repeat units (n=4, 8, 12, 16, etc.). By controlling the polymerization to produce oligomers with precise repeat unit numbers rather than continuous distribution, the method achieves monodispersity while maintaining versatility across different molecular weights for various applications.
Solution Approach 2:
The invention changes the critical parameter of molecular weight distribution from polydisperse to monodisperse by controlling the polymerization process to produce oligomers with specific repeat unit numbers. This parameter change enables precise molecular weight control while preserving the wide applicability of PEG compounds in pharmaceuticals, cosmetics, and industrial uses.
2Reliability
If polydisperse PEGs are used in PEG-protein conjugates, then stabilization and extended circulation half-life are achieved, but heterogeneity reduces reproducibility
Solution Approach 1:
The invention applies segmentation by producing PEG oligomers with precise repeat unit numbers (n=4, 8, 12, 16) rather than continuous distributions. This segmentation into discrete molecular weight species enables reproducible PEG-protein conjugates with consistent stability enhancement and circulation half-life extension, eliminating the heterogeneity problems of polydisperse PEGs.
Solution Approach 2:
The invention changes the molecular weight distribution parameter from polydisperse to monodisperse, producing PEG oligomers with specific repeat unit numbers. This parameter change ensures reproducible conjugation results while maintaining the stability and circulation half-life benefits observed with PEG-modified proteins.
3Productivity
If conventional PEG synthesis methods are used, then production efficiency is maintained, but polydispersity and multicomponent nature cause purification difficulties
Solution Approach 1:
The invention segments the PEG product into discrete oligomer species with specific repeat unit numbers through controlled polymerization. This segmentation produces monodisperse products that are significantly easier to purify compared to polydisperse conventional PEGs, as each oligomer species can be separated and isolated with high purity using standard techniques.
Solution Approach 2:
The invention changes the molecular weight distribution from continuous (polydisperse) to discrete (monodisperse) by controlling the polymerization to produce oligomers with specific repeat unit numbers. This parameter change dramatically simplifies purification while maintaining production efficiency, as monodisperse products require less complex separation processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the production of discrete, monodispersed PEG compounds that overcome the challenges of polydispersity, enhancing the reproducibility and therapeutic efficacy of PEG-modified proteins and oligonucleotides by providing a wider range of molecular weights and improved purification processes, suitable for commercial manufacturing.
Implementation Method 1
Commercial PEG's are produced by anionicaly initiated polymerization of ethylene oxide
Implementation Method 2
polyethylene glycols are a family of polymers produced from the condensation of ethylene glycol, usually initiated with base
Data Source
AI summary
Aspects of the present invention are directed to novel methods for making discrete polyethylene compounds selectively and specifically to a predetermined number of ethylene oxide units. Methods which can be used to build up larger dPEG compounds (a) containing a wider range of utility to make useful homo- and heterofunctional and branched species, and (b) under reaction configurations and conditions that are milder, more efficient, more diverse in terms of incorporating useful functionality, more controllable, and more versatile then any conventional method reported in the art to date. In addition, the embodiments of the invention allow for processes that allow for significantly improving the ability to purify the intermediates or final product mixtures, making these methods useful for commercial manufacturing dPEGs. Protecting groups and functional groups can be designed to make purification at large scale a practical reality. The novel dPEG products form the compositional and material basis for making other novel compounds of valuable application in the fields of diagnostics and therapeutics, amongst others.